Biosimilars Market Trends and Overview

The market size of biosimilars was valued at USD 25.10 billion in 2022 and is projected to reach USD 91.81 billion by 2030, with a compound annual growth rate (CAGR) of 17.6% during the forecast period from 2023 to 2030.

Biosimilars, which are highly similar versions of approved biological products, have gained significant traction in the pharmaceutical industry. This market segment has witnessed substantial growth due to the increasing demand for cost-effective alternatives to expensive biologic drugs. The rising prevalence of chronic diseases, coupled with the need for affordable treatment options, has fueled the adoption of biosimilars.

The anticipated growth in the biosimilars market can be attributed to several factors. Firstly, the expiration of patents for several biologic drugs has opened doors for biosimilar manufacturers to enter the market and offer more affordable alternatives. Additionally, the regulatory framework surrounding biosimilars has become more streamlined, providing a conducive environment for market expansion.

Furthermore, the growing emphasis on healthcare cost containment and the need to reduce the burden on healthcare systems have propelled the adoption of biosimilars. These products offer comparable efficacy and safety profiles to their reference biologics, making them an attractive option for healthcare providers and patients alike.

Geographically, North America and Europe have dominated the biosimilars market, owing to favorable regulatory policies and a well-established healthcare infrastructure. However, emerging economies in Asia-Pacific and Latin America are expected to witness significant growth in the coming years, driven by increasing healthcare expenditure and a rising demand for affordable treatment options.

In conclusion, the biosimilars market is poised for substantial growth in the coming years, driven by factors such as patent expirations, regulatory advancements, and the need for cost-effective healthcare solutions. As the market expands, it presents lucrative opportunities for manufacturers and stakeholders to capitalize on the growing demand for biosimilar products.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/2941

KEY MARKET SEGMENTATION:

By Type

• Human growth hormone
• Erythropoietin
• Monoclonal antibodies
• Insulin
• Granulocyte-Colony Stimulating Factor

By Application

• Blood disorders
• Oncology diseases
• Chronic and autoimmune diseases

Major Players Listed in the Report are as Follows:

Dr Reddy’s Laboratories, Eli Lilly and Company, Pfizer Inc., Intas Pharmaceutical Ltd, Biocon Ltd, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Limited, Kashiv BioSciences, reliance life sciences

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com